Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 35 Spray characterization for the low-GWP era Low-GWP propellants are reshaping pMDI refor- mulation strategy. Changes in vapor pressure, plume dynamics and suspension behavior demand renewed spray characterization to ensure performance equiv- alence and stability. Proveris Laboratories deliver detailed spray pattern, plume geometry, plume front velocity, APSD and shaking studies to sup- port regulatory- ready data and reduce reformulation risk. We help sponsors move confidently from legacy HFAs to next-generation propellants. Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proverislabs.com Integrated solutions for pulmonary and nasal delivery With 30+ years' experience in pulmonary and nasal delivery, Catalent offers integrated solutions with clinical- to commercial-scale development and man- ufacturing capabilities for spray-dried or micronized dry powders for inhalation, capsules for inhalation and unit-dose, bi-dose and multi-dose nasal liquid and powder products, including sterile vials for neb- ulization of small molecules and biopharmaceuticals. In addition, Catalent provides comprehensive ana- lytical and clinical supply services to support your molecule from development through product launch and beyond. With state-of-the-art facilities in Boston, Massachusetts and Morrisville, North Carolina, US, Catalent can handle the most complex projects and help bring your inhaled therapy to market, faster. Catalent US: +1 888 SOLUTION (765-8846) solutions@catalent.com www.catalent.com Role of excipients for respiratory delivery Building upon more than 20 years of experience, Lonza continues to drive research in formulation for inhaled delivery of biologics. Excipient choice in drug formulation plays a key role in this process, and when combining a large molecule with one or more excip- ients, factors such as their own properties, route of administration, dosage form and processing condi- tions need to be considered. With dedicated technol- ogies and facilities, Lonza's scientists are identifying new, leading approaches with excipients and provid- ing support for navigating the regulatory landscape. Lonza Small Molecules US: +1 813 286-0404 small.molecules@lonza.com www.lonza.com Understanding nasal drug delivery and performance e location of nasal drug delivery depends on the API, formulation, device and intended target site. MedPharm's MedCast™ nasal cast model uses CT-based, 3D-printed casts to quantify drug deposi- tion within specific regions of the nasal cavity based on the formulation and device combination. Beyond deposition, our reconstructed nasal epithelial (RNE) model uses primary human nasal epithelial cells to recreate key features of the nasal barrier, including cilia, mucus production and tight junctions, enabling further evaluation of formulation performance. MedPharm US: 919 514-3460 busdev@medpharm.com www.medpharm.com

